INHIBITORS OF HOXA9 LEUKEMOGENIC TRANSCRIPTION FACTOR ARE EFFICIENT ON HUMAN AML CELL MODELS BUT NOT ON NORMAL HUMAN BONE MARROW CD34+ HEMATOPOIETIC CELLS
EHA Library, Marie-Helene David-Cordonnier, 266623
NORMAL AND LEUKEMIC BONE MARROW STROMAL CELLS HAVE DIFFERENT CAPACITIES FOR MITOCHONDRIA TRANSFER TO ACUTE MYELOID LEUKEMIA CELLS
EHA Library, Mariane Cristina do Nascimento, 266624
A NEW NEXT-GENERATION SEQUENCING STRATEGY FOR THE SIMULTANEOUS DETECTION OF GENE MUTATIONS AND COPY NUMBER VARIATIONS IN MYELOID MALIGNANCIES
EHA Library, Ramon Garcia-Sanz, 266625
PREFERENTIAL TRANSCRIPTION OF THE MUTATED ALLELE IN NPM1 MUTATED ACUTE MYELOID LEUKAEMIA
EHA Library, Graham Bailey, 266639
MUTANT IDH1 INHIBITOR IVOSIDENIB (AG-120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
EHA Library, Courtney D. DiNardo, 266640
IMPACT OF MINIMAL RESIDUAL DISEASE AND COMPLETE REMISSION (CR)/CR WITH PARTIAL HEMATOLOGIC RECOVERY ON SURVIVAL AFTER GILTERITINIB THERAPY IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML
EHA Library, Mark Levis, 266641
FLT3 TESTING IN THE RYDAPT ERA
EHA Library, Stuart Scott, 266655
ROBUST IDENTIFICATION OF CLINICALLY RELEVANT MUTATIONS IN AML USING RNA-SEQ
EHA Library, Muxin Gu, 266656
DETECTION OF MRD MAY PREDICT THE OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH BIALLELIC CEBPA MUTATIONS
EHA Library, Jing wang, 266657
INTENSIFIED CONDITIONING WITH FLUDARABINE/MELPHALAN PLUS TOTAL BODY IRRADIATION VERSUS FLUDARABINE/MELPHALAN ALONE FOR ACUTE MYELOID LEUKEMIA
EHA Library, Sarah Lindner, 266671
NEGATIVE MINIMAL RESIDUAL DISEASE STATUS BY MULTICOLOUR FLOW CYTOMETRY AFTER 1ST COURSE IS THE MOST PREDICTIVE FACTOR FOR AML PATIENTS
EHA Library, Tatiana Lobanova, 266672
ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME WITH CHROMOSOME 17 ABNORMALITIES AND LONG-TERM OUTCOMES WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Library, Ghulam Rehman Mohyuddin, 266673
SURVIVAL OF B-CELL LYMPHOMAS IN THE PRE- AND POST-RITUXIMAB ERAS: 30 YEARS REAL-WORLD DATA
EHA Library, Mohamed Gouda, 266689
PRELIMINARY RESULTS OF ASTX660, A NOVEL NON-PEPTIDOMIMETIC CIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA
EHA Library, Amitkumar Mehta, 266690
SANDOZ RITUXIMAB FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA: INTERIM SAFETY RESULTS OF THE PROSPECTIVE NON-INTERVENTIONAL, OBSERVATIONAL, MULTICENTER, OPEN-LABEL REFLECT STUDY
EHA Library, Manfred Welslau, 266691
A RETROSPECTIVE COHORT STUDY TO EVALUATE THE OUTCOMES OF HIV-ASSOCIATED HIGH-GRADE B-CELL NON-HODGKIN LYMPHOMA (NHL) TREATED WITH DOSE ADJUSTED R EPOCH REGIMEN
EHA Library, Jayshree Thorat, 266705
PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE
EHA Library, Theodoros Vassilakopoulos, 266706
OBINUTUZUMAB DOES NOT COMPROMISE MOBILIZATION AND ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN LYMPHOMA PATIENTS: RESULTS FROM A FIL PROSPECTIVE PHASE II STUDY (THE GIOTTO STUDY)
EHA Library, Roberta BATTISTINI, 266707
CONGENITAL DEFICIENCY OF COAGULATION FACTOR VII IN THE SOUTH OF TUNISIA: ABOUT 88 CASES.
EHA Library, Safouan Kacem, 266722
A RETROSPECTIVE ANALYSIS OF IMMUNE THROMBOCYTOPENIA PATIENTS TREATMENT RESULTS AFTER SEQUENTIAL SWITCHING OF THROMBOPOIETIC RECEPTOR-AGONISTS
EHA Library, Maria Pankrashkina, 266723
IMPACT OF SEVERITY OF THE DISEASE AND FVIII INHIBITOR ON BONE MINERAL DENSITY AND BONE TURNOVER MARKER IN CHILDREN WITH HEMOPHILIA A
EHA Library, Panagiota Xafaki, 266724
IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY
EHA Library, Jenny Wu, 266740
IBRUTINIB TREATMENT ALTERS ENHANCER ACTIVITY PATTERNS IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Library, Efterpi Kostareli, 266741
LINKING MICROENVIRONMENTAL SIGNALS TO METABOLIC SWITCHES AND IBRUTINIB RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Library, Zhenghao Chen, 266742
P300 INDUCES STAT3 ACETYLATION AND PROVIDES CLL CELLS WITH SURVIVAL ADVANTAGE
EHA Library, Uri ROZOVSKI, 266756
THE IMBALANCE OF THE NON-LEUKEMIC COMPARTMENT SUSTAINS THE LYMPHOPROLIFERATION IN T-LARGE GRANULAR LYMPHOCITYES LEUKEMIA
EHA Library, Cristina Vicenzetto, 266757
PROTEOMICS MARKERS PROGNOSTIC FOR OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER TREATMENT; RESULTS FROM THE HOVON-109 STUDY
EHA Library, Fatemeh Saberi Hosnijeh, 266758
A PHASE I/II STUDY OF THE SYK INHIBITOR ENTOSPLETINIB IN COMBINATION WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
EHA Library, Alexey Danilov, 266772
HAMPERED EFFECTIVENESS OF SECOND-LINE TREATMENT WITH RITUXIMAB-BASED CHEMOTHERAPY WITHOUT SIGNS OF RITUXIMAB RESISTANCE: A POPULATION-BASED STUDY AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Library, Lina van der Straten, 266773
EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL
EHA Library, Paolo Ghia, 266774
TELOMERE LENGTH AT DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA PREDICTS THE ACHIEVEMENT OF DEEP MOLECULAR RESPONSE TO IMATINIB
EHA Library, Natalia ESTRADA, 266788
DDPCR AT THE TIME OF TKI DISCONTINUATION IN CHRONIC PHASE CHRONIC MYELOID PATIENTS IS PREDICTIVE OF TREATMENT-FREE REMISSION OUTCOME
EHA Library, Gioia colafigli, 266789
ASSOCIATION OF CELLULAR IMMUNITY WITH MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS ON TYROSINE KINASE INHIBITORS THERAPY
EHA Library, Milan Jagurinoski, 266804
AN UPDATED META-ANALYSIS OF THE RISKS OF ARTERIAL AND VENOUS OCCLUSIVE EVENTS WITH NEW GENERATION BCR-ABL TKIS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
EHA Library, Jonathan Douxfils, 266805
Hereditary spherocytosis: screening and diagnostic approach in a Belgian laboratory
EHA Library, Edith Sepulchre, 266820
SEVERE HEREDITARY HAEMOLYTIC ANAEMIA DUE TO THREE NOVEL SPTA1 MUTATIONS IN TWO COMPOUND HETEROZYGOUS UNRELATED PATIENTS.
EHA Library, Joan-LLuis Vives Corron, 266821
CAUSES OF NON - ELIGIBILITY FOR CD19 CAR T-CELL IMMUNOTHERAPY IN PATIENTS WITH RELAPSE/REFRACTORY DLBCL. EXPERIENCE OF SAINT-LOUIS HOSPITAL
EHA Library, Jérôme PAILLASSA, 266836
EX-VIVO HEMATOPOIETIC STEM CELL GENE THERAPY (GT) FOR MUCOPOLYSACCHARIDOSIS TYPE I HURLER (MPSIH): PRELIMINARY RESULTS FROM A PHASE I/II CLINICAL STUDY
EHA Library, Maria Ester BERNARDO, 266837
COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF MULTIPLE TREATMENT STRATEGIES USING ABVD AND/OR BEACOPP IN THE TREATMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA
EHA Library, Abi Vijenthira, 266853
DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI‐CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI
EHA Library, Rita Mazza, 266854
MAGNIFY: PHASE IIIB INTERIM ANALYSIS OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
EHA Library, Mathias J. Rummel, 266870
CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA AFTER RETREATMENT WITH SECOND-LINE RITUXIMAB-CONTAINING CHEMOTHERAPY
EHA Library, Jiajia Liu, 266871
AUTOIMMUNE NEUTROPENIA OF INFANCY- UNEXPECTED PREVALENCE OF PSEUDOMONAS SKIN INFECTIONS
EHA Library, Joanne Yacobovich, 266886
HIGH INCIDENCE OF CYTOMEGALOVIRUS (CMV) REACTIVATION IN HEMATOLOGICAL PATIENTS TREATED WITH BENDAMUSTINE BASED CHEMOTERAPY REGIMENS
EHA Library, Rosario Bianco, 266887
INVASIVE FUNGAL DISEASES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS WITH HODGKIN’S LYMPHOMA
EHA Library, Yuliya Rogacheva, 266902
INVASIVE YEAST INFECTIONS IN HEMATOLOGICAL PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Library, Yuliya Rogacheva, 266903
POTENT ANTI-TUMOR ACTIVITY OF DUOBODY®-CD3XCD20 IN PRECLINICAL MODELS IN VITRO AND IN VIVO
EHA Library, Ida Hiemstra, 266918
THE CD58-CD2 AXIS CONTROLS KILLING OF B CELLS BY CYTOTOXIC T CELLS
EHA Library, Anna KABANOVA, 266919
VITAMIN D3 INHIBITS GROWTH OF HODGKIN CELL LINES AND IMPROVES SENSITIVITY TO CHEMOTHERAPY AT PHYSIOLOGICAL DOSES IN VITRO AND IN VIVO.
EHA Library, Melita Cirillo, 266934
LONG TERM FOLLOW-UP OF WALDENSTRÖM MACROGLOBULINEMIA PATIENTS PRIMARY TREATED WITH DEXAMETHASONE, RITUXIMAB, AND CYCLOPHOSPHAMIDE : A SINGLE CENTRE EXPERIENCE
EHA Library, vittorio del fabro, 266935
OVEREXPRESSION OF PROTEIN TYROSINE PHOSPHATASE NON-RECEPTOR TYPE1 CAUSES STAT5 DEPHOSPHORYLATION, RESULTING IN SUPPRESSION OF CELL GROWTH SIGNAL IN K562 HUMAN LEUKEMIA CELLS
EHA Library, Masayuki SHISEKI, 266950
THERAPEUTIC RESPONSE OF MYELODYSPLASTIC SYNDROMES TO EPIGENETIC DRUGS INDEPENDENTLY OF ENDOGENOUS RETROELEMENT MODULATION
EHA Library, Zoi Bezirgiannidou, 266951
UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA
EHA Library, María-Victoria Mateos, 266966
STRONG PRE-CLINICAL RATIONAL FOR THE USE OF MCL1/BCL2 BH3 MIMETIC COMBINATION TO EFFECTIVELY KILL PRIMARY MYELOMA CELLS INSENSITIVE TO EACH BH3 MIMETIC ALONE
EHA Library, Carolane Seiller, 266967
COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN
EHA Library, Takashi Kanamori, 266984
IGH AND IGK REARRANGEMENT AND IGH SOMATIC HYPERMUTATION ANALYSIS USING NEXT-GENERATION SEQUENCING FOR THE DETECTION OF CLONALITY IN HIGH-RISK KOREAN MULTIPLE MYELOMA PATIENTS
EHA Library, Jiwon Lee, 266985
A SEQUENTIAL COHORT STUDY COMPARING KAPPAMAB ALONE TO KAPPAMAB, LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN KAPPA-RESTRICTED RELAPSED REFRACTORY (RR) MULTIPLE MYELOMA (AMARC 01-16)
EHA Library, Anna KALFF, 267000
TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY
EHA Library, Sundar Jagannath, 267001
REAL WORLD DATA ON THE EFFICACY AND SAFETY OF DARATUMUMAB FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS: A MULTI-SITE RETROSPECTIVE STUDY.
EHA Library, Yael C Cohen, 267016
ASSESSMENT OF SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA BY USING MODIFIED RISK STRATIFICATION MSMART 3.0
EHA Library, S. Voloshin, 267017
SURVIVAL OF MULTIPLE MYELOMA PATIENTS DIAGNOSED 1970-2015: REAL-WORLD DATA FROM A SINGLE CENTER
EHA Library, Luis Gerardo Rodríguez-Lobato, 267032
EVOLVING TREATMENT PATTERNS IN NON-STEM CELL TRANSPLANT (NSCT) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS FROM A REAL-WORLD CHART REVIEW IN FRANCE, GERMANY, AND THE UK
EHA Library, Dorothy Romanus, 267033
IDENTIFICATION OF THE TRUE HYPERDIPLOID MULTIPLE MYELOMA SUBSET BY COMBINING CONVENTIONAL KARYOTYPING AND FISH ANALYSIS
EHA Library, Gregorio Barilà, 267048
3-WEEKLY DARATUMUMAB-IMID-DEXAMETHASONE IS HIGHLY EFFICACIOUS, HENCE FINANCIALLY AFFORDABLE WITH ENORMOUS ECONOMIC IMPACT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN LESS AFFLUENT COUNTRIES
EHA Library, Chor Sang Chim, 267049
LIN-CD133+CD34+CD41+ HSPC REPRESENT A MEGAKARYOCYTE-PRIMED NEOPLASTIC FRACTION IN MPN PATIENTS WITH MYELOFIBROSIS
EHA Library, Vera Koehl, 267065
DISSECTING THE THERAPEUTIC MECHANISM OF RUXOLITINIB IN JAK2V617F MEDIATED MPNS REVEALED AN INHIBITION OF BOTH ONCOGENIC AND NON-ONCOGENIC CELLS BY DOWN REGULATION OF INFLAMMATORY CYTOKINE LEVELS
EHA Library, Sivahari Prasad Gorantla Gorantla, 267066
INTERFERON ALPHA HAS STRONG ANTI-TUMOR EFFECT IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
EHA Library, Patrizia Mondello, 267081
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL
EHA Library, Francisco Cervantes, 267082
PLATELET REACTIVITY AND RESPONSE TO ANTIPLATELET DRUGS IN THROMBOCYTOPENIA AND THROMBOCYTOSIS
EHA Library, Lidia USNARSKA-ZUBKIEWICZ, 267098
EFFECT OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS) ON ENDOTHELIAL CELLS AND NEUTROPHIL EXTRACELLULAR TRAP (NET) FORMATION IN IMMUNE THROMBOCYTOPENIA (ITP)
EHA Library, Lamya Garabet, 267099
INCREASED RHOA ACTIVITY DUE TO A DISRUPTED FILAMIN A/ALPHAIIBΒETA3 INTERACTION INDUCES MACROTHROMBOCYTOPENIA
EHA Library, Alessandro Donada, 267115
THE EMOTIONAL IMPACT OF WATCH AND WAIT FOR CLL
EHA Library, Zack Pemberton-Whiteley, 267116
PARTICIPATION IN A SPECIALISED EXERCISE INTERVENTION IMPROVED PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH HAEMATOLOGICAL CANCERS
EHA Library, Jennifer Nicol, 267131
PREMEDICATION WITH MONTELUKAST AND RUPATADINE DECREASES INFUSION TIME, RATE AND SEVERITY OF REACTIONS AND OVERALL COST OF RITUXIMAB ADMINISTRATION
EHA Library, Rouslan Kotchetkov, 267132
POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED AND HAPLOIDENTICAL TRANSPLANT RECIPIENTS RECEIVING MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN CONDITIONING REGIMEN: RESULTS OF A PHASE II STUDY
EHA Library, Rohtesh Mehta, 267147
INCIDENCE, RISK FACTOR AND OUTCOME OF IMMUNE-MEDIATED NEUROPATHIES FOLLOWING HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Library, Xiying Ren, 267148
LONG-ACTING G-CSF (LIPEGFILGRASTIM, “LONQUEX”) FOR STEM CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
EHA Library, Ivetta Danylesko, 267164
SAFETY AND EFFICACY OF CANNABIDIOL FOR SEVERE ACUTE GRAFT VERSUS HOST DISEASE - A PHASE I/II STUDY
EHA Library, Liat shargian-alon, 267165
HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH DETECTABLE DISEASE AT TRANSPLANT
EHA Library, Samer A. Srour, 267181
REPETITIVE SUPPLEMENTS OF TGF-Β1 INDUCED REGULATORY T CELLS PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE IN MOUSE MODEL
EHA Library, Tzeon-Jye Chiou, 267182
AN EPIDEMIOLOGIC STUDY OF PREGNANCY RELATED VENOUS THROMBO-EMBOLISM IN SOUTH AFRICA: ARE HIV INFECTED WOMEN A NEW HIGH-RISK GROUP?
EHA Library, Elise schapkaitz, 267196
PREVALENCE AND RISK FACTORS FOR THROMBOSIS IN ADULT ITP PATIENTS TREATED WITH TPO-RA
EHA Library, Maria Lozano, 267197
COMPLEMENT SYSTEM ANALYSES IN PATIENTS SUSPECTED TO HAVE ATYPICAL HEMOLYTIC UREMIC SYNDROME
EHA Library, Jorge M. Nieto, 267198
PREVENTING ALLOIMMUNIZATION OF RECIPIENTS WITH SELECTING OF DONORS BY RED BLOOD CELLS ANTIGENS OF THE RHESUS SYSTEM
EHA Library, Elena Butina, 267212
AUTOIMMUNIZATION AND ALLOIMMUNIZATION IN TRANSFUSION DEPENDANT THALASSEMIA MAJOR PATIENTS:STUDY ON 300 PATIENTS
EHA Library, Ayesha younas, 267213
PHOSPHOCHROMATOME ANALYSIS UNCOVERS UNEXPECTED ROLES OF CDK6 IN REGULATING TRANSCRIPTION
EHA Library, Sofie Nebenfuehr, 267228
“3C-UP” A NEW ADULT PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUBGROUP: NOVEL MOLECULAR MARKERS
EHA Library, Anna Ferrari, 267229
SENSITIZATION OF PH+ ALL RESISTANT TO IMATINIB BY TARGETING SPHINGOLIPID METABOLISM
EHA Library, Yagmur KIRAZ, 267231
KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3
EHA Library, Bijal D. Shah, 267246
BLINATUMOMAB + PONATINIB FOR RELAPSED PH1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: THE FRENCH EXPERIENCE.
EHA Library, Marie-Anne COUTURIER, 267247
THE SUCCESSFUL APPLICATION OF ANTI-CD19 CAR-T THERAPY TO PATIENTS WITH CENTRAL NERVE SYSTEM B-CELL ACUTE LYMPHOCYTIC LEUKEMIA
EHA Library, Liyun Chen, 267248
PATIENTS WITH RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA HAVE SHORT REMISSION DURATION WITH RE-INDUCTION: A SINGLE CENTER EXPERIENCE
EHA Library, Claire Andrews, 267262
PHASE 1 RESULTS OF ZUMA-4: KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Library, Alan S. Wayne, 267263
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: DOES MINIMAL RESIDUAL DISEASE BEFORE TRANSPLANTATION MATTER FOR LONG TERM OUTCOME?
EHA Library, Ángela Figuera Álvarez, 267264
DISCOVERY OF NOVEL C/D BOX SNORNAS THAT ARE REQUIRED FOR LEUKEMIA CELL PROLIFERATION
EHA Library, Andreas Kienast, 267279
PI3K INHIBITION COMBINED WITH STANDARD CHEMOTHERAPY EFFECTIVELY INHIBITS KIT MUTANT AML
EHA Library, Montserrat Estruch, 267280
GRIK5 DRIVES SELF RENEWAL PATHWAYS IN HUMAN ACUTE MYELOID LEUKEMIA CELLS
EHA Library, Jianglong Xia, 267281
IMPACT OF DNMT3A MUTATIONAL STATUS IN MOLECULAR MEASURABLE RESIDUAL DISEASE CLEARANCE IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1
EHA Library, Guadalupe Oñate, 267296
TCF4 IS IMPORTANT FOR MUTANT RUNX1-MEDIATED CELL IMMORTALIZATION AND PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA
EHA Library, Florentien intHout, 267297
A NEW BIOMARKER OF RESPONSE TO 5-AZACITIDINE THERAPY IN MDS AND AML PATIENTS: SIRPB1
EHA Library, Claudio CERCHIONE, 267298

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings